Novartis AG vs Upwork Inc — how do they compare? Novartis AG trades at $153.29 (market cap $295.37B), while Upwork Inc trades at $8.2 (market cap $1.04B). The key difference: Novartis AG is far larger — about 284× Upwork Inc's market cap, and Novartis AG pays a 3.07% dividend while Upwork Inc pays none. Which is the better fit depends on your goals.
| NVS | UPWK | |
|---|---|---|
Market Cap | $295.37B | $1.04B |
Sector | Health | Industrials |
52-Week High | $168.62 | $22.11 |
52-Week Low | $119.31 | $7.84 |
Enterprise Value | $336.69B | $806.15M |
Dividend Yield | 3.07% | — |
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
UPWK trades at $9.83, up 1.65% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 EPS of $0.41, beating expectations, but revenue guidance disappointed investors, causing a recent stock decline. Fundamentals show solid profitability with a 12.93% net income margin and attractive valuation ratios, including a P/E of 10.71. Cash flow from operations remains strong at $248.26 million for 2025.
The outlook is mixed: strong fundamentals and analyst buy ratings support upside potential, but weak guidance and active client declines pose near-term risks. Investment opportunity lies in valuation appeal and AI integration, balanced by execution challenges in a competitive freelance market.
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →